For which age group is the FluMist Quadrivalent (LAIV4) influenza vaccine approved?

The FluMist Quadrivalent (LAIV4) influenza vaccine is specifically approved for use in individuals aged 2 to 49 years. This nasal spray vaccine provides an alternative to the injectable flu vaccine and is a live attenuated influenza vaccine, which means it contains weakened forms of the virus to help the immune system build protection.

The approval for this age range allows for immunization of healthy pediatric patients as well as adults, enhancing community immunization efforts, particularly in settings where nasal administration may be preferred due to factors like patient comfort or logistics.

Younger infants, specifically those under 6 months of age, are excluded from receiving this vaccine because their immune systems are still developing significantly. Options specifying age groups younger than 2 or older than 49 fail to comply with the established safety and efficacy data supporting the use of FluMist in the indicated age range.